Trial Profile
A Phase II Trial Investigating the Benefit of Immunotherapy With Durvalumab After Autologous Transplant in High-risk Diffuse-large B-cell Lymphomas (the IDA-D Trial)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 19 Jun 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Acronyms IDA-D
- 05 Apr 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 09 Aug 2017 New trial record